1LIN CHANG,MD.From Rome to Los Angeles-The Rome Ⅲ criteria functional gI Disorders.
2THOMSON AB,BARKUN AN,ARMSTRONG D,et al.The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia:The canadian adult dyspepsia empiric treatment-prompt endoscopy(CADET-PE)[J].Aliment Pharmacol Ther,2003,17:1481.
3A ERSRYD,I POSSERD,H ABRAHAMSSON.M.SIMREN subtyping the irritable bowel syndrome by predominant bowel habit:RomeⅡ versus Rome Ⅲ:Alimentary pharmacology and therapeutics.2007,26(6):953.
4CAMILLERI M,CHEY WY,MAYER EA,et al.A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome[J].Arch Intern Med,2001,161:1733.
5CHEY WD.Review article:tegaserod-the global experience[J].Ali-ment Pharmacol Ther,2004,20(Suppl 7):15.
6MULLER-LISSNER SA,FUMAGALLI I,BARDHAN KD,et al.Tegaserod,a 5-HT4 receptor partial agonist,relieves symptoms in irritable bowel syndrome patients with abdominal pain,bloating and constipation[J].Aliment Pharmscol Ther,2001,15:1655.
